MSI2

Across TCGA pan-cancer cohorts, MSI2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MSI2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MSI2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MSI2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and OV are the cancer types where MSI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.868	0.506	.002	48	view →
CCRCC	DFS	Quartile	II,III,IV	0.887	0.198	.024	14	view →
OV	DFS	Median	All	0.841	1.000	.017	12	view →
GBM	OS	Quartile	All	0.715	0.390	.008	7	view →
HNSC	OS	Median	All	0.621	0.809	.011	4	view →
UCEC	DFS	Tertile	All	0.918	0.733	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MSI2–PDAC (DFS)

Open the PDAC breakdown →